676479-06-4

Upstream product

• 456-42-8 m-fluorobenzyl chloride 
• 123-30-8 4-amino-phenol 
• 754228-95-0 (S)-3-acetylamino-y-butyrolactone 
• 4910-47-8 N-Acetyl-asparaginsaeure-α-methylester 
• 57289-64-2 N-α-acetyl-L-aspartic acid α,β-dimethylester 
• 676479-40-6 (S)-4-amino-1-[4-(3-fluoro-benzyloxy)-phenyl]-pyrrolidin-2-one hydrochloride 
• 75-36-5 acetyl chloride 
• 910298-84-9 (S)-1-[4-(3-fluoro-benzyloxy)-phenyl]-5-oxo-pyrrolidine-3-carboxylic acid amide 
• 108-24-7 acetic anhydride 

Downstream Products

• 676479-53-1 (S)-N-[1-(4-hydroxy-phenyl)-5-oxo-pyrrolidin-3-yl]-acetamide 

Relevant academic research and scientific papers

CRYSTALLINE FORMS OF A PYRROLIDONE DERIVATIVE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE AND PREPARATION THEREOF

The present invention provides processes to manufacture crystalline N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide. Also disclosed are polymorphic forms of said compound as well as compounds useful as intermediates in the methods of the invention.

Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives

The invention relates to a method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives of formula I: wherein R1, R21, R22, R23, R24 and n are as defined the description and claims and to intermediates and salts thereof useful in the method of the invention.

Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives

The invention relates to a method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives of formula I: wherein R1, R21, R22, R23, R24 and n are as defined in the description and claims and to intermediates useful in the method of the invention as well as salts thereof.

Process for the preparation of enantiopure pyrrolidin-2-one derivatives

The present invention relates to a process for the preparation of enantiopure intermediates useful in the synthesis of valuable pharmaceutically active compounds, e.g. MAOB inhibitors, and to novel intermediates of formulae I and II wherein R21

PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS

Racemic or enantiomerically pure 4-pyrrolidino derivatives of the formula (I), processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of a disease which is mediated by a mono